​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Active ​​​​CAVD Grantees - ​Alphabetized List

Browse the list of Consortia below to learn more about each CAVD Grant. ​

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A

• Appel: Injectable Hydrogels for the Ultra-Long-Term Stabilization and Delivery of Antibodies​
  

B ​​

• ​​​​Batista: Mouse Genomic Manipulation Platform for Accelerated Vaccine Design​​
• ​Busch: Validation of Existing and Ultra-Sensitive Assays for Qualifying HIV Persistence ​​​

Return to top

C

• Corey: Support for HVTN 702
  

Return to top

​ D

E

F

• Feinberg: IAVI Neutralizing Antibody Consortium

Return to top

G

• Gaiha: Multi-networked T cell epitope vaccine for global HIV prevention and therapy ​
  
• Gallo: FLSC Phase I & II Clinical Trials
• Gottardo: VISC
  
• ​ Gupta: Clinical Assessment of Live Attenuated hCMV-HIV Prototype Vector

Return to top

H

• Hassell: CAVD Alliance Management
  
• ​Hassell: Vaccine Product Development Center
• Hassell: Vaccine Product Development Center: GMP Manufacturing, Toxicology, and Clinical Data Management
  
• Haynes: MPER-Peptide Liposome Immunogen Testing
• Haynes: Protein Expression Facility
• Himansu​: mRNA Encoded Abs for HIV Prophylaxis
  
• Ho: First in human clinical evaluation of 10E8.4/iMab, a potent and broad bispecific antibody against HIV

Return to top

I

 Return to top

J

• ​​Johnson: Single Cell Transcriptional Profiling of Latently-Infected CD4+ T Cells​​
• ​​Jolicoeur: Development of a new class of immunogens for raising broadly neutralizing antibodies ​​

Return to top

K

• ​ Koup: Comprehensive Cellular Vaccine Immune Monitoring Consortium
• Kublin: HVTN 705: A phase 2b clinical trial to evaluate the efficacy of Ad26 recombinant HIV vaccine + gp140

Return to top

L

• Lusso: mRNA-Encoded HIV-1 Env-Gag Virus-Like-Particle (VLP) Vaccines​

Return to top

M 

• ​​McElrath: Durability of HIV-specific protective Ab responses in human immunology-based experimental medicine trials
• ​​Montefiori: Ab VIMC
• ​​​​Moore: Next generation BG505 SOSIP.664-trimer based lineage HIV vaccines
• Mullins: Improving infection time estimators using PacBio sequencing​

Return to top

N

• Ndung’u: African Collaboration for Innovation in HIV/TB Prevention
  
• ​ Ndung’u: Profiling Virus Neutralization in the KwaZulu-Natal FRESH Cohort​
  
• Nussenzweig: Clinical Trial of Broadly Neutralizing anti-HIV Antibodies
• Nussenzweig: ​​Phase 1 studies of the pharmacokinetics, safety, and bioactivity of 3BNC117-LS and 10-1074-LS among adults in the US and sub-Saharan Africa
  

Return to top

O

 P

• ​​Pantaleo: Final stage optimization of LN02 for pre-development (LN02op)​
  
• Picker: An Attenuated CMV Vector
• ​Picker: MHC II and MHC E-Restricted CD8+ T Cells and Control of HIV
• Pulendran: Protective humoral responses against HIV

Return to top

Q

R 

​

S 

• Sajadi: Development of a new family of potent and broad neutralizing antibodies​

• Sanders: HIV Trimer Immunogens to Elicit bNAbs against Multiple Epitopes

• ​​​​Schief: Experimental Medicine FIH of mRNA-HIV Immunogens

• ​Shaw: Germline targeted SOSIPs and SHIVs to elicit V2 apex bNAbs
  

Return to top

T

• ​ ​Thomas: Just Biotherapeutics Support for HIV bNAbs

U

Return to top

V

Return to top

W 

• ​ ​​​Ward: Analytics Network for Characterization of HIV Env immunogens, Formulation ​​​

Return to top

X

Y

Z

Return to top

​